These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6168909)

  • 21. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder.
    Das K; Zhao Y; Sugiono M; Lau W; Tan PH; Cheng C
    Urol Oncol; 2007; 25(4):317-21. PubMed ID: 17628298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
    Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
    J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer.
    Theodoropoulos VE; Lazaris ACh; Sofras F; Gerzelis I; Tsoukala V; Ghikonti I; Manikas K; Kastriotis I
    Eur Urol; 2004 Aug; 46(2):200-8. PubMed ID: 15245814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum and urine ferritin in patients with transitional cell carcinoma of the bladder.
    Migliari R; Mela Q; Ruggiero V; Scarpa RM; Migliari M; Pitzus F; Usai E
    Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):141-5. PubMed ID: 1830406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
    Shariat SF
    Eur Urol; 2009 Oct; 56(4):688-9. PubMed ID: 18513852
    [No Abstract]   [Full Text] [Related]  

  • 26. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
    Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
    Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of quantitative examination of urine MUC1 in bladder transitional cell carcinoma].
    Xiang ST; Zhou SW; Guan W; Hu ZQ; Zhuang QY; Ye ZQ
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):998-1000. PubMed ID: 16109559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer.
    Lokeshwar VB; Obek C; Soloway MS; Block NL
    Cancer Res; 1997 Feb; 57(4):773-7. PubMed ID: 9044859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.
    Johannes JR; Nelson E; Bibbo M; Bagley DH
    J Urol; 2010 Sep; 184(3):879-82. PubMed ID: 20643443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
    Li G; Yang T; Li L; Yan J; Zeng Y; Yu J; Zhang Y
    Colloids Surf B Biointerfaces; 2004 Aug; 37(1-2):15-9. PubMed ID: 15450303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Urine cytology in the diagnosis of urothelium tumors].
    Rona-Selnic G
    Med Lab (Stuttg); 1982; 35(6):158-62. PubMed ID: 7162453
    [No Abstract]   [Full Text] [Related]  

  • 33. [Urinary cytology in superficial transitional cell carcinoma of the bladder].
    Nissenkorn I; Slutzker D; Schujman E; Slutzki S; Servadio C
    Harefuah; 1983 Dec; 105(12):400-1. PubMed ID: 6674064
    [No Abstract]   [Full Text] [Related]  

  • 34. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
    Mohammed SI; Bennett PF; Craig BA; Glickman NW; Mutsaers AJ; Snyder PW; Widmer WR; DeGortari AE; Bonney PL; Knapp DW
    Cancer Res; 2002 Jan; 62(2):356-8. PubMed ID: 11809678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of urine cytology in urological practice.
    Highman WJ
    Acta Urol Belg; 1983; 51(1):7-11. PubMed ID: 6858799
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical significance of dysplastic squamous cells in exfoliative urine cytology.
    Rosa M
    Diagn Cytopathol; 2010 Jun; 38(6):468-9. PubMed ID: 19937764
    [No Abstract]   [Full Text] [Related]  

  • 38. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth.
    Schweigerer L; Neufeld G; Friedman J; Abraham JA; Fiddes JC; Gospodarowicz D
    Nature; 1987 Jan 15-21; 325(6101):257-9. PubMed ID: 2433585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical modeling of capillary formation and development in tumor angiogenesis: penetration into the stroma.
    Levine HA; Pamuk S; Sleeman BD; Nilsen-Hamilton M
    Bull Math Biol; 2001 Sep; 63(5):801-63. PubMed ID: 11565406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder.
    Chodak GW; Haudenschild C; Gittes RF; Folkman J
    Ann Surg; 1980 Dec; 192(6):762-71. PubMed ID: 6160821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.